Assessing covariate imbalance in meta-analysis studies

Statistics in Medicine

Volumn 30, Issue 22, 2011, Pages 2671-2682

  Aiello, Fabio ^a   Attanasio, Massimo ^b   Tinè, Fabio ^c  

^a KORE UNIVERSITY OF ENNA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Ospedali Riuniti Villa Sofia e Cervello   (Italy)

Author keywords

Combinability; ECDF; Non parametric test; Perturbation

Indexed keywords

ALPHA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANALYSIS OF COVARIANCE; ANDERSON DARLING TEST; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DATA EXTRACTION; DEMOGRAPHY; DRUG EFFICACY; EMPIRICAL RESEARCH; EXPERIMENTAL STUDY; HEPATITIS C; HUMAN; KOLMOGOROV SMIRNOV TEST; META ANALYSIS (TOPIC); OUTCOMES RESEARCH; PARAMETRIC TEST; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; VASCULAR DISEASE;

DATA INTERPRETATION, STATISTICAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERFERON-ALPHA; MALE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052850706     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4311     Document Type: Article

References (26)

1. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. The New England Journal of Medicine 1987; 316(8):450-455.
2. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in Medicine 1999; 18:2693-2708.
3. st century. Journal of Clinical Epidemiology 1995; 48(1):71-79.
4. Schimdt CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. Journal of Clinical Epidemiology 2004; 57:683-697. DOI: 10.1016/j.jclinepi.2003.12.001.
5. Macarthur C, Foran PJ, Bailar III JC. Qualitative assessment of studies included in a meta-analysis: DES and the risk of pregnancy loss. Journal of Clinical Epidemiology 1995; 48(6):739-747.
6. Siersma V, Als-Nielsen B, Chen W, Hilden J, Gluud LL, Gluud C. Multivariable modelling for meta-epidemiological assessment of the association between trial quality and treatment effect estimated randomized clinical trials. Statistics in Medicine 2007; 26:2745-2758. DOI: 10.1002/sim2752.
7. Berlin JA, Rennie D. Measuring the quality of trials. The quality of quality scales. Journal of the American Medical Association 1999; 282(11):1083-1085.
8. Normand SL. Meta-analysis: formulating, evaluating, combining and reporting. Statistics in Medicine 1999; 18(3):321-359.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, G and Oslash;tzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009; 62:e1-e34. DOI: 10.1016/j.jclinepi.2009.06.006.
10. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. When does it make sense to perform a meta-analysis? In Introduction to Meta-analysis, Vol. 19. John Wiley & Sons, Ltd: Chichester, UK, 2009.
11. Lipsey MW. Identifying potentially interesting variables and analysis opportunities. In The Handbook of Research Synthesis, Cooper H, Hedges LV (eds). Russell Sage Foundation: New York, 1994.
12. Altman DG. Covariate imbalance, adjustment for. In Encyclopaedia of Biostatistics, Armitage P, Colton T (eds). John Wiley & Sons, Ltd: Chichester, 1998; 1000-1005.
13. Altman DG. Comparability of randomised groups. The Statistician 1985; 34(1):125-136.
14. Trowman R, Dunville JC, Torgerson DJ, Cranny G. The impact of trial baseline imbalances should be considered in systematic reviews: a methodological case study. Journal of Clinical Epidemiology 2007; 60(12):1229-1233. DOI: 10.1016/j.jclinepi.2007.03.014.
15. Tinè F, Attanasio M, Russo F, Pagliaro L. A decade of trials of interferon-alpha for chronic hepatitis C. A meta-regression analysis. Contemporary Clinical Trials 2005; 26:179-210. DOI: 10.1016/j.cct.2004.12.009.
16. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. The Lancet 2005; 366:1267-1278. DOI: 10.1016/S0140-6736(05)67394-1.
17. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. The Lancet 2008; 371:117-125. DOI: 10.1016/S0140-6736(08)60104-X.
18. Scholz FW, Stephens MA. K-sample Anderson-Darling Tests. Journal of the American Statistical Association 1987; 82(399):918-924.
19. D'Agostino RB, Stephens MA. Goodness-of-fit techniques. Statistics, textbooks and monographs, Vol. 68. Marcel Dekker Inc: New York, 1986.
20. Pettitt AN. A two-sample Anderson-Darling rank statistic. Biometrika 1976; 63:161-168.
21. Altman M, Gill J, McDonald MP. Numerical Issues in Statistical Computing for the Social Scientist. John Wiley & Sons: 2003.
22. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2009. ISBN 3-900051-07-0, URL.
23. Berger VW, Weinstein S. Ensuring the comparability groups: is randomization enough? Controlled Clinical Trials 2004; 25:515-524. DOI: 10.1016/j.cct.2004.04.001.
24. Preston C, Ashby D, Smyth R. Adjusting for publication bias: modeling the selection process. Journal of Evaluation of Clinical Practice 2004; 10(2):313-322. DOI: 10.1111/j.1365-2753.2003.00457.x.
25. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special references to studies of the association between exposure to environmental tobacco smoke and lung cancer; a critique. Journal of Clinical Epidemiology 1991; 44(2):127-139.
26. Copas JB, Li HG. Inference for non-random samples. Journal of the Royal Statistical Society B 1997; 59(1):55-95.